News
A phase I study of a next-generation CAR T cell therapy showed a 52 percent complete remission rate for patients with relapsed/refractory lymphoma. A next-generation "armored" CAR T cell therapy ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback